US Earnings Financial Results SEC Filings — April 06, 2026

06-04-2026

STRATEGIC ACQUISITIONS INC reported a reduced net loss of $40,223 for the year ended December 31, 2025, compared to $123,716 in 2024 (restated), driven by lower operating expenses ($40,223 vs. $144,822) and elimination of interest expense. However, revenue dropped to $0 from $43,671, primarily due to no interest income from Bitcoin-collateralized loans after full principal repayment in 2024, while cash plummeted 98% to $508 and total assets declined 78% to $5,388 amid reduced liabilities to $13,319.

• ·Basic and diluted net loss per share improved to $(0.01) from $(0.02).
• ·Net cash used in operating activities decreased to $30,473 from $110,124.
• ·Stockholders’ equity deficit narrowed to $(7,931) from $(81,029).
• ·Non-cash capital contribution of $11,000 for expenses paid on behalf of the company in 2025.
• ·No loans receivable or digital asset collateral remaining at end of 2025.

06-04-2026

iQSTEL Inc reported net revenue of $316,899,498 for the year ended December 31, 2025, up 11.9% YoY from $283,220,442 in 2024, driven by strong growth in IoT Labs LLC (+24.6% to $117,370,459), QXTEL Limited (+48.0% to $141,624,991), SwissLink Carrier AG (+67.8% to $22,394,346), and new subsidiary GlobeTopper LLC ($27,955,101). However, significant declines occurred in Etelix.com USA, LLC (-57.9% to $31,748,230), Smartbiz Telecom (-40.5% to $12,743,474), and Whisl Telecom (-32.2% to $2,916,447), while cost of revenue rose to $307,442,244 (+11.9% YoY). Q4 2025 revenue fell 14.9% to $84,215,893 from $98,920,186, though gross margin improved slightly to 3.46% from 2.74%.

• ·Issued 75,529 shares as stock dividend valued at $500,000.
• ·Issued 3,563 shares for common stock payable valued at $82,194.
• ·(9) shares issued for reverse stock split adjustment.
• ·Intercompany eliminations reduced revenue by $41,841,186 in 2025 (vs $22,818,982 in 2024).

06-04-2026

Elvictor Group, Inc. (ELVG) reported total revenue of $2,427,968 for the year ended December 31, 2025, up 0.3% YoY from $2,421,308, with gross revenue increasing 1.5% to $1,871,292; however, net revenue declined 3.6% to $556,676 and gross profit fell 3.4% to $1,805,223 amid higher costs. The company swung to a net loss of $175,719 (EPS -$0.21) from a $199,780 profit (EPS $0.24) in 2024, driven by operating expenses rising 19% to $2,014,960, resulting in an operating loss of $209,737 versus a $177,519 profit. Positively, cash improved to $490,974 from $101,089 with operating cash flow of $418,351 versus a $583,519 outflow, and management executed nine new crew management contracts in Q1 2026 expected to materially boost revenue.

• ·Total current liabilities increased to $1,492,125 as of Dec 31, 2025 from $1,099,152.
• ·Cash flows from operating activities turned positive at $418,351 in 2025 from -$583,519 in 2024.
• ·Management pursuing additional capital through equity and other financing for working capital and diversification.
• ·Audited by RBSM LLP (PCAOB ID #587).

06-04-2026

Shepherd's Finance, LLC's 2025 net income declined 19% YoY to $1,413 thousand from $1,737 thousand, driven by a 25% rise in SG&A expenses to $3,824 thousand and higher provisions for credit losses at $1,066 thousand, despite net interest and fee income increasing 7% to $5,732 thousand. Net income attributable to common equity holders plunged 59% to $425 thousand from $1,035 thousand, while non-interest income fell 6% to $3,644 thousand amid lower revenue from land sales and option fees. Weighted average outstanding loan balances decreased 5% to $52,941 thousand, with total unpaid balances at $61,683 thousand showing 94.9% current but 5.1% past due.

• ·Total non-interest expense increased to $6,897 thousand in 2025 from $6,734 thousand in 2024.
• ·Delinquency breakdown: 2.3% 60-89 days past due ($1,439 thousand), 1.8% 90-179 days ($1,157 thousand), 0.7% 180-269 days ($446 thousand), 0.3% >270 days ($134 thousand).

06-04-2026

For the nine months ended September 30, 2025, Nutra Pharma Corp reported total net sales of $331,241, up 22.4% YoY from $270,620, driven by a 39.1% increase in non-related party sales to $228,748, with gross profit rising 29.7% to $208,535. However, operating expenses surged 40.0% to $1,204,959, resulting in a widened net loss of $1,558,866 (47.8% worse YoY), cash burned $944,146 in operations (vs. $245,749 prior), and ending cash fell 90.1% to $3,603. Total assets grew 18.4% to $709,853, but liabilities increased 10.8% to $17,060,633 and stockholders' deficit deepened 10.4% to $16,350,780.

• ·Net cash used in operating activities for nine months ended Sep 30, 2025: $944,146 (vs. $245,749 in 2024)
• ·Cash flows from financing activities provided $962,354 for nine months ended Sep 30, 2025
• ·Investment in Stemsation stocks: $17,600 (unchanged)
• ·Receivable from sale of Stemsation stocks: $52,800 (unchanged)

06-04-2026

The 10-K annual report for Corporate Backed Trust Certificates, Goldman Sachs Capital I Securities-Backed Series 2004-6 Trust covers the fiscal year ended December 31, 2025, and incorporates trustee distribution statements from Form 8-K filings rather than providing direct financial statements or analysis. The Trust holds solely capital securities issued by Goldman Sachs Capital I, with investors directed to The Goldman Sachs Group, Inc.'s SEC filings for underlying details; no material events such as legal proceedings, accountant changes, or operational risks are reported.

• ·Certificates registered with Cede & Co. and listed on NYSE
• ·Trust formed March 19, 2004, per Series Supplement
• ·Distribution statements filed on Form 8-K for dates including 02/15/2025, 08/15/2025, 02/28/2025, 08/28/2025
• ·No voting stock or common equity held by non-affiliates

06-04-2026

SolarMax Technology reported total revenue of $90.982M for 2025, up 296% YoY from $22.987M, primarily driven by $60.172M in new large-scale EPC contracts, with gross profit rising 83% to $4.230M; however, gross margin declined to 4.6% from 10.1% amid higher costs, and net loss narrowed to $6.324M from $34.963M. The company faces significant challenges including defaults on $14.3M of EB-5 convertible notes, $10.5M in related-party secured debt ($5.5M current), Nasdaq non-compliance due to sub-$1.00 stock price, and a $1.0M overdue receivable from SPIC. A significant internal control deficiency over financial disclosures was remediated by December 31, 2025, but prior non-disclosure of defaults poses market risks.

• ·Customer loans receivable gross declined to $3.337M in 2025 from $4.644M in 2024, with allowance for losses at $0.206M vs $0.280M.
• ·Non-current customer loans portion $2.256M in 2025 vs $3.076M in 2024.
• ·Asset impairment in China $0 in 2025 vs $7.462M in 2024.
• ·Weighted average exercise price of outstanding options/warrants: $5.01 (approved plans), $3.50 (unapproved).
• ·Received Nasdaq notice for non-compliance with $1.00 minimum bid price requirement.

06-04-2026

Neolara Corp. reported zero revenue for both Q1 FY2026 (three months ended September 30, 2025) and the prior year period, remaining flat at $0. Net loss widened dramatically to $(73,621) from $(4,586) YoY, driven by a $46,062 impairment of intangible assets, $19,685 write-off of prepaid advisory fees, and higher G&A expenses, while total assets dropped to $0 QoQ from $67,469 amid full impairment and depletion of cash to $0. However, stockholders' deficit improved to $(2,051) from $(23,343) QoQ due to $90,713 in related party advances forgiven and contributed to capital plus $4,200 cash contribution.

• ·Amortization expense remained flat at $688 YoY.
• ·Net cash used in operating activities improved to $(5,331) from $(23,898) YoY.
• ·Intangible assets fully impaired: cost $55,000 less accumulated amortization $8,938 and impairment $46,062, net $0 as of Sep 30, 2025.
• ·Cash capital contribution of $4,200 from related party.
• ·Net loss per share: $(0.02) vs $(0.00) YoY.